H
Description
Oncology immunotherapy company headquartered in South San Francisco, California, developer of a novel class of T-cell engagers (TriTAC® platform). Acquired by Merck for $680 million in 2025. Lead candidate HPN328 targets DLL3 in small cell lung cancer.